Applied Therapeutics Files 8-K on Operations and Other Events

TL;DR

APLT filed an 8-K on 8/12 detailing 8/11 operational and financial updates.

AI Summary

Applied Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on events that occurred on August 11, 2025. The filing pertains to the company's results of operations and financial condition, as well as other events.

Why It Matters

This 8-K filing provides updates on Applied Therapeutics' financial condition and operational developments, which are crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on operational and financial matters, not indicating any immediate or significant new risks.

Key Players & Entities

• Applied Therapeutics, Inc. (company) — Registrant
• August 11, 2025 (date) — Date of earliest event reported
• August 12, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 212 220-9226 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 APLT The Nasdaq Global Market Ind
• $17.4 million — ty as of June 30, 2025 is approximately $17.4 million. The Company has not yet completed it
• $1.00 — mon Stock"), has been below the minimum $1.00 per share required (the "Bid Price Requ
• $5 million — rice Requirement, including the minimum $5 million stockholders' equity requirement. Howev

Filing Documents

• aplt-20250811.htm (8-K) — 50KB
• 0000950170-25-106700.txt ( ) — 152KB
• aplt-20250811.xsd (EX-101.SCH) — 23KB
• aplt-20250811_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 11, 2025, Applied Therapeutics, Inc. (the "Company") announced that the preliminary unaudited estimate of its total stockholders' equity as of June 30, 2025 is approximately $17.4 million. The Company has not yet completed its quarter-end financial close process for the quarter ended June 30, 2025. The foregoing information is based on preliminary unaudited information and management estimates for the quarter ended June 30, 2025, is not a comprehensive statement of the Company's financial results, and is subject to completion of the Company's financial closing procedures. There can be no assurance that the Company's actual financial results as of June 30, 2025 will not differ from these estimates, including as a result of the completion of the Company's final adjustments, and other developments arising between the date of this filing and the time that the Company's financial results for such period are finalized, and any such changes could be material. These preliminary unaudited estimates have been prepared by, and are the responsibility of, the Company's management. Ernst & Young LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto. These estimates should not be viewed as a substitute for interim financial statements prepared in accordance with accounting principles generally accepted in the United States and they are not necessarily indicative of the results to be achieved in any future period. Complete results as of June 30, 2025 will be included in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 or in the corresponding earnings release. The Company intends to timely file such Form 10-Q and earnings release on August 13, 2025. The Company assumes no duty to update these

01 Other Events

Item 8.01 Other Events. As previously reported, on February 7, 2025, the Company received a notification letter (the "Bid Price Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock, par value $0.0001 per share (the "Common Stock"), has been below the minimum $1.00 per share required (the "Bid Price Requirement") for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was given 180 calendar days, or until August 6, 2025, to regain compliance with the Bid Price Requirement pursuant to Nasdaq Listing Rule 5450(a)(1). The Bid Price Letter also noted if the Company does not regain compliance by August 6, 2025, the Company may be eligible for an additional 180 calendar day remediation period if it transfers the listing of the Common Stock to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company met these requirements, the Bid Price Letter stated that Nasdaq would inform the Company that it has been granted an additional 180 calendar days. The Company has submitted an application to transfer the listing of the Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market. As of the date of this filing, the Company believes that it meets the continued listing requirement for market value of publicly held shares and all initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Requirement, including the minimum $5 m

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding (i) the Company's preliminary unaudited interim financial information and (ii) the Company's continued listing on the Nasdaq Stock Market LLC, including its ability to meet and maintain the listing requirements for the Nasdaq Capital Market, its ability to regain and maintain compliance with the Bid Price Requirement, and Nasdaq's determination regarding the Company's continued listing. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company's business are described in detail in its Securities and Exchange Commission ("SEC") filings, including in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APPLIED THERAPEUTICS, INC. Date: August 11, 2025 By: / s/ Les Funtleyder Les Funtleyder, Interim Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR